NVAX JPM Corporate Presentation January 2026.pdf

1、 2026 NOVAVAX.All rights reserved.1Novavax Corporate PresentationJohn C.Jacobs,President and Chief Executive OfficerJ.P.Morgan Healthcare Conference 2026 NOVAVAX.All rights reserved.1 2026 NOVAVAX.All rights reserved.2We envision a world where our technology is amplified to touch the lives of billio

2、ns,sparking transformation in global health.This is Novavax 2026 NOVAVAX.All rights reserved.2 2026 NOVAVAX.All rights reserved.3Cautionary Note Regarding Forward-Looking StatementsThis presentation includes forward-looking statements.These forward-looking statements generally can be identified by t

3、he use of words such as“anticipate,”“expect,”“plan,”“could,”“may,”“will,”“believe,”“estimate,”“forecast,”“goal,”“project,”and other words of similar meaning.These forward-looking statements address various matters including Novavaxs corporate strategy and operating plans,objectives and prospects;its

4、 value drivers and near-term priorities;its partnerships,including expectations with respect to potential royalties,milestones,and cost reimbursement,and plans for additional potential partnering activities;its expectations regarding manufacturing capacity,timing,production and delivery for its COVI

5、D-19 vaccine;the transition of the lead responsibility for commercialization of Novavaxs COVID-19 vaccine to Sanofi beginning with the 2025-2026 vaccination season the development of Novavaxs clinical and preclinical product candidates and pipeline advancement;the conduct,timing and potential result

6、s from clinical trials and other preclinical and postmarketing studies;scope,timing and outcome of future and pending regulatory filings and actions;potential future market sizes and demand for its COVID-19 vaccine and product candidates;the conduct of our post marketing commitment(“PMC”)study reque